Heron Therapeutics Stock Soars After Court Ruling
On Wednesday, Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotech firm, saw a significant pre-market stock price increase of 66% following a favorable ruling from the U.S. District Court in Delaware. The court sided with Heron in its patent litigation against Fresenius Kabi USA, LLC regarding the drug CINVANTI® (aprepitant) injectable emulsion.
The litigation started in July 2022 when Heron initiated a lawsuit after Fresenius submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval for a generic version of CINVANTI®. The court's ruling validated Heron's U.S. Patent Nos. 9,561,229 and 9,974,794, which remain valid until 2035, and concluded that Fresenius's proposed generic product infringes upon these patents.
Following the court's decision, Heron plans to request an order preventing Fresenius from launching its generic version of CINVANTI® until after the patents expire. However, it's important to note that this ruling is subject to appeal.
Craig Collard, the CEO of Heron, expressed his satisfaction with the ruling: "We are pleased with this anticipated result of the proceeding and will continue to vigorously defend the CINVANTI® patent estate in the future." He also emphasized the company's commitment to developing injectable products and the strength of their intellectual property.
This ruling marks a significant victory for Heron, protecting the company's exclusive rights to market CINVANTI® until patent expiration. This injectable emulsion serves an essential role in addressing serious unmet needs in patient care.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Comments (0)